These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25301170)

  • 41. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.
    Pandey SK; Wheeler TM; Justice SL; Kim A; Younis HS; Gattis D; Jauvin D; Puymirat J; Swayze EE; Freier SM; Bennett CF; Thornton CA; MacLeod AR
    J Pharmacol Exp Ther; 2015 Nov; 355(2):329-40. PubMed ID: 26330536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-
    Pirie E; Cauntay P; Fu W; Ray S; Pan C; Lusis AJ; Hsiao J; Burel SA; Narayanan P; Crooke RM; Lee RG
    Nucleic Acid Ther; 2019 Oct; 29(5):266-277. PubMed ID: 31368839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey.
    Henry SP; Johnson M; Zanardi TA; Fey R; Auyeung D; Lappin PB; Levin AA
    Toxicology; 2012 Nov; 301(1-3):13-20. PubMed ID: 22709826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
    Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of coagulation by a phosphorothioate oligonucleotide.
    Henry SP; Novotny W; Leeds J; Auletta C; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):503-10. PubMed ID: 9361909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral delivery of antisense oligonucleotides in man.
    Tillman LG; Geary RS; Hardee GE
    J Pharm Sci; 2008 Jan; 97(1):225-36. PubMed ID: 17721945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
    Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis).
    Umeda S; Suzuki MT; Okamoto H; Ono F; Mizota A; Terao K; Yoshikawa Y; Tanaka Y; Iwata T
    FASEB J; 2005 Oct; 19(12):1683-5. PubMed ID: 16099945
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity Assessment of Inotersen, a 2'-
    Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
    Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
    Shemesh CS; Yu RZ; Gaus HJ; Seth PP; Swayze EE; Bennett FC; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Aug; 26(4):223-35. PubMed ID: 27031383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
    Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
    Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies of monkey complement: measurement of cynomolgus monkey CH50, ACH50, C4, C2 and C3.
    Xu H; Kitano E; Sato Y; Kobayashi C; Firdawes S; Kitamura H; Fukuzawa M; Miyagawa S
    Xenotransplantation; 2008 Feb; 15(1):14-9. PubMed ID: 18333909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
    N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
    Loyet KM; Good J; Davancaze T; Sturgeon L; Wang X; Yang J; Le KN; Wong M; Hass PE; van Lookeren Campagne M; Haughney PC; Morimoto A; Damico-Beyer LA; DeForge LE
    J Pharmacol Exp Ther; 2014 Dec; 351(3):527-37. PubMed ID: 25232192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates.
    Slingsby MHL; Vijey P; Tsai IT; Roweth H; Couldwell G; Wilkie AR; Gaus H; Goolsby JM; Okazaki R; Terkovich BE; Semple JW; Thon JN; Henry SP; Narayanan P; Italiano JE
    Haematologica; 2022 Feb; 107(2):519-531. PubMed ID: 33567808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates.
    Østergaard ME; Jackson M; Low A; E Chappell A; G Lee R; Peralta RQ; Yu J; Kinberger GA; Dan A; Carty R; Tanowitz M; Anderson P; Kim TW; Fradkin L; Mullick AE; Murray S; Rigo F; Prakash TP; Bennett CF; Swayze EE; Gaus HJ; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6045-6058. PubMed ID: 31076766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.